Details

Autor(en) / Beteiligte

• Sen, Hanim
• Tandjung, Kenneth
• Basalus, Mounir W Z
• Löwik, Marije M
• van Houwelingen, Gert K
• Stoel, Martin G
• Louwerenburg, Hans W
• de Man, Frits H A F
• Linssen, Gerard C M
• Nijhuis, Rogier
• Nienhuis, Mark B
• Verhorst, Patrick M J
• van der Palen, Job
• von Birgelen, Clemens

Titel

Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and Xience V drug-eluting stents

Ist Teil von

• EuroIntervention, 2012-10, Vol.8 (6), p.664-671

Ort / Verlag

France

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• The TWENTE trial recently enrolled more than 80% of all eligible patients, who were randomised to zotarolimus-eluting Resolute or everolimus-eluting XIENCE V stents. In the present study, we investigated whether eligible, non-enrolled patients differed from the randomised TWENTE trial population in baseline characteristics and one-year outcome. Characteristics of 1,709 eligible patients were analysed. Independent external adjudication of clinical events was likewise performed for non-enrolled (n=318) and randomised patients (n=1,391). Non-enrolled and randomised patients did not differ in gender distribution, diabetes mellitus, and clinical presentation, but differed significantly in age and cardiovascular history. Nevertheless, clinical outcome after one year did not differ in the primary composite endpoint target-vessel failure (TVF; 9.8% vs. 8.1%; p=0.34), and its components cardiac death (1.6% vs. 1.2%; p=0.61), target vessel-related myocardial infarction (4.7% vs. 4.6%; p=0.92), and target-vessel revascularisation (3.8% vs. 3.0%; p=0.48). Previous bypass surgery predicted TVF in non-enrolled patients (p=0.001); removal of these patients resulted in identical TVF rates for non-enrolled and randomised patients (7.3% vs. 7.3%; p=0.99). Despite some differences in baseline characteristics, non-enrolled and randomised patients did not differ in one-year outcome, which was favourable for both populations and may be related to the drug-eluting stents used.